Pet Cancer Therapeutics Market Size By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Combination Therapy), By Route of Administration (Oral, Injection), By Species (Dogs, Cats), By Application (Lymphoma, Mast Cell Cancer, Melanoma, Mammary and S

Pet Cancer Therapeutics Market Size By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Combination Therapy), By Route of Administration (Oral, Injection), By Species (Dogs, Cats), By Application (Lymphoma, Mast Cell Cancer, Melanoma, Mammary and Squamous Cell Cancer), Industry Analysis Report, Regional Outlook, Growth Potential, COVID-19 Impact Analysis, Price Trends, Competitive Market Share & Forecast, 2022 - 2030

The pet cancer therapeutics market is set to grow enormously through 2030 owing to rising prevalence of pet cancer. In addition, surging awareness among pet owners about pet diseases, along with escalating pet adoption is likely to enhance industry expansion over the forecast period.

Recent awareness regarding pet health among pet owners has accelerated market growth. During the COVID-19 pandemic, the industry witnessed a surge in adoption. Ongoing advancements in the therapeutic process have also bolstered overall business growth. Moreover, major players in the pet cancer therapeutics market have been focusing on effective innovations in pet cancer technologies and strategic acquisitions & collaborations to propel their industry standing.

For instance, in April 2022, Elanco Animal Health, an American pharmaceutical company, in collaboration with a biotech firm Ginkgo Bioworks launched BiomEdit, a new animal health company, which was intended to focus on bioactive molecules, microbial monitoring services, novel probiotics, and engineered microbial medicines for animal health. This move was expected to help Elanco address the unmet needs observed in the animal health care system.

In another instance, in December 2021, life sciences expert Qbiotics launched STELFONTA, its lead veterinary drug for canine non-metastatic mast cell tumors (MCT), in Australia after it was greenlit by the Australian Pesticides and Veterinary Medicines Authority (APVMA). Similarly, in April 2022, Anivive Lifesciences, a pet pharmaceutical company, announced that Dechra Pharmaceuticals PLC, a manufacturer of veterinary products, acquired the license for Laverdia-CA1, a novel treatment for canine lymphoma.

The pet cancer therapeutics market has been bifurcated on the basis of therapy, route of administration, species, application, and region.

In terms of therapy, the industry has been segregated into immunotherapy, combination therapy, chemotherapy, and targeted therapy. The combination therapy segment is slated to grow significantly over the review period. This form of therapy incorporates two or more therapeutic treatments to detect and eliminate cancerous cells effectively while also maintaining the pet’s quality of life.

From the application perspective, the pet cancer therapeutics industry has been divided into lymphoma, mast cell cancer, mammary and squamous cell cancer, melanoma, and others. The mast cell cancer segment is slated to observe considerable progress through 2030. The bone marrow, spleen, liver, and gastrointestinal system are among the organs that are impacted by mast cell tumors, which is speculated to fuel the adoption of therapeutics for this cancer type significantly in the forthcoming years.

In the regional context, the Latin America pet cancer therapeutics market is estimated to expand remarkably through the analysis time period. Increasing knowledge pertaining to pet cancer and the available therapeutics is set to prove beneficial for pet cancer therapeutics in the LATAM region.